1. In Vivo
  2. >>Deal-Making

In Vivo's Deals Of The Month, September 2017

 
• By Nancy Dvorin

In Vivo's editors pick September's most significant deals, including lucrative partnerships for Halozyme and the pursuit of Dimension Therapeutics. (Free article.)

IV_DOTM_1200

Bristol-Myers Squibb Co. will pay $105 million up front and as much as $1.76 billion in milestones to use Halozyme Therapeutics Inc.'s Enhanze technology to develop subcutaneous versions of drugs against up to 11 immuno-oncology targets. [See Deal] The deal has the potential to be Halozyme's most lucrative to date. Also in September, Halozyme announced that Roche will pay $30 million up front and up to $160 million in milestone fees to add a target to their existing partnership. [See Deal]

September was rife with biopharma spin-offs including SpringWorks Therapeutics LLC,which launched from Pfizer Inc. with four clinical-stage assets and concurrently raised $103 million in Series A venture capital from the big pharma as well as Bain Capital Life Sciences, Bain Capital Double Impact, Orbimed and LifeArc. SpringWorks' compounds target diseases with no good treatment options: desmoid tumors, neurofibromatosis, hereditary xerocytosis and PTSD

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.